Search the Studies

71 Studies found from all possible combinations of your search terms. Select a protocol that you wish to review.
Protocol Number Title Protocol Status Min-Max Age Institute Keywords
001084-CHA Prospective Natural History Study of Lymphatic AnomaliesParticipants currently recruited/enrolled0-125 YearsNICHDCentral
000821-IAn Open-Label, Single-Arm, Phase 1/2 Dose-Escalation Trial of Long-Acting Recombinant Human IL-7 (NT-I7, Efineptakin Alfa) for Idiopathic CD4 LymphopeniaRecruitment has not started18-75 YearsNIAIDCentral
000516-CPhase 1 Study of Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (VIPOR) for Diffuse Large B-cell Lymphoma involving the Central Nervous SystemParticipants currently recruited/enrolled18-125 YearsNCI Central
000489-CPhase I/II Study Using Prophylactic Donor Lymphocyte Infusion Early Post-Transplant After Allogeneic Hematopoietic Cell Transplantation Using Post-Transplantation Cyclophosphamide for High-Risk Hematologic MalignanciesClinical hold/Recruitment or enrollment suspended12-125 YearsNCI Central
000404-CA Phase II Study of Allogeneic Hematopoietic Stem Cell Transplant for Subjects with VEXAS (Vacuoles, E1 enzyme, X-linked, Autoinflammatory, Somatic) SyndromeParticipants currently recruited/enrolled18-75 YearsNCI Central
000359-CPhase I/II study to reduce post-transplantation cyclophosphamide dosing for older or unfit patients undergoing bone marrow transplantation for hematologic malignanciesParticipants currently recruited/enrolled12-85 YearsNCI Central
000293-CManaging Cancer and Living Meaningfully (CALM) Therapy in Individuals Diagnosed with a Primary Central Nervous System TumorEnrolling by Invitation18-125 YearsNCI Central
000186-IPart B- Phase I/II, Non-randomized, Multicenter, Open-label Study of G1XCGD (Lentiviral Vector Transduced CD34+ Cells) in Patients with X-Linked Chronic Granulomatous DiseaseClinical hold/Recruitment or enrollment suspended3-12 YearsNIAIDCentral
000085-CAssessing Sleep and Circadian Rhythms in Primary Brain Tumors Patients: An Observational StudyEnrolling by Invitation18-99 YearsNCI Central
22-C-0003Feasibility of Evaluating Abemaciclib Neuropharmacokinetics of Diffuse Midline Glioma Using Intratumoral MicrodialysisParticipants currently recruited/enrolled18-39 YearsNCI Central
21-I-0003A Phase 1/2 Study to Evaluate the Safety, Tolerability and Efficacy, of JSP191 for Hematopoietic Cell Transplantation Conditioning to Achieve Engraftment and Immune Reconstitution in Subjects with SCIDParticipants currently recruited/enrolled3-125 YearsNIAIDCentral
21-C-0032GD2-CAR PERSIST: Production and Engineering of GD2-Targeted, Receptor Modified T Cells (GD2CART) for Osteosarcoma or Neuroblastoma to Increase Systemic Tumor ExposureParticipants currently recruited/enrolled0-35 YearsNCI Central
21-C-0030Phase I Study of GPC3 Targeted CAR-T Cell Therapy in Advanced GPC3 Expressing Hepatocellular Carcinoma (HCC)Participants currently recruited/enrolled18-125 YearsNCI Central
21-C-0022A Phase 2 Single Arm Open-Label Clinical Trial of ADP-A2M4 SPEAR(TM) T Cells in Subjects with Advanced Synovial Sarcoma or Myxoid/Round Cell LiposarcomaParticipants currently recruited/enrolled10-75 YearsNCI Central
20-I-0111COVID-19-associated Lymphopenia Pathogenesis Study in BloodParticipants currently recruited/enrolled18-125 YearsNIAIDCentral
20-I-0037Matched Related and Unrelated Donor Stem Cell Transplantation for Severe Combined Immune Deficiency (SCID): Busulfan-based Conditioning with h-ATG, Radiation, and SirolimusEnrolling by Invitation3-40 YearsNIAIDCentral
20-H-0033Early Initiation of Oral Therapy with Cyclosporine and Eltrombopag for Treatment Naive Severe Aplastic Anemia (SAA)Participants currently recruited/enrolled3-125 YearsNHLBICentral
20-E-0143Serological Surveillance for COVID-19 in Central North CarolinaParticipants currently recruited/enrolled18-125 YearsNIEHSCentral
20-C-0121Rapid Analysis and Response Evaluation of Combination Anti-Neoplastic Agents in Rare Tumors (RARE CANCER) Trial: RARE 1 Nilotinib and PaclitaxelParticipants currently recruited/enrolled18-125 YearsNCI Central
20-C-0070A Phase II Study of Allogeneic Hematopoietic Stem Cell Transplant for Patients with Inborn Errors of ImmunityParticipants currently recruited/enrolled4-69 YearsNCI Central
20-C-0069A First-In-Human Phase I Single-Agent Dose-Escalation, Food Effect and Dose Expansion Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System NeoplasmsParticipants currently recruited/enrolled18-125 YearsNCI Central
20-C-0028Phase 1/2 Study of Anti-CD33 Chimeric Antigen Receptor-Expressing T Cells (CD33CART) in Children and Young Adults with Relapsed/Refractory Acute Myeloid LeukemiaParticipants currently recruited/enrolled3-35 YearsNCI Central
19-N-0124Anakinra for the Treatment of Chronically Inflamed White Matter Lesions in Multiple SclerosisParticipants currently recruited/enrolled18-120 YearsNINDSCentral
19-I-0080Haploidentical Transplant for Patients with Chronic Granulomatous Disease (CGD) using Alemtuzumab, Busulfan and TBI with Post-Transplant CyclophosphamideParticipants currently recruited/enrolled4-65 YearsNIAIDCentral
19-HG-0101A Phase 1/2 Study of Intravenous Gene Transfer with an AAV9 Vector Expressing Human Beta-galactosidase in Type I and Type II GM1 GangliosidosisNo longer recruiting/follow-up only0-12 YearsNHGRICentral
19-C-0128A Phase I Study of Mesothelin-Targeted Immunotoxin LMB-100 in Combination with Tofacitinib in Persons with Previously Treated Pancreatic Adenocarcinoma, Cholangiocarcinoma and other Mesothelin Expressing Solid TumorsCompleted Study; data analyses ongoing18-125 YearsNCI Central
19-C-0103A Study of Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib, and Rituximab (TEDDI-R) in Aggressive B-cell Lymphomas with Secondary Involvement of the Central Nervous System (CNS)Participants currently recruited/enrolled18-125 YearsNCI Central
19-C-0102A Phase I Clinical Trial of T-cells Expressing an anti-SLAMF7 CAR for Treating Multiple MyelomaCompleted Study; data analyses ongoing18-73 YearsNCI Central
18-C-0125A Phase I Clinical Trial of T cells Expressing a Novel Fully-human Anti-BCMA CAR for Treating Multiple MyelomaNo longer recruiting/follow-up only18-73 YearsNCI Central
18-C-0026A Phase 2 Study of Inotuzumab Ozogamicin (NSC# 772518, IND#133494) in Children and Young Adults with Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL)Participants currently recruited/enrolled1-21 YearsNCI Central
17-I-0122NIAID Centralized Sequencing ProtocolParticipants currently recruited/enrolled0-125 YearsNIAIDCentral
17-H-0069Nonmyeloablative Haploidentical Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Sickle Cell DiseaseParticipants currently recruited/enrolled2-125 YearsNHLBICentral
17-EI-0112A Long-term Follow-up Study of Participants Enrolled in 11-EI-0147: Longitudinal Investigation of Dark Adaptation in Participants with Age-Related Macular Degeneration (DA_AMD)Participants currently recruited/enrolled50-125 YearsNEI Central
17-EI-0008The Natural History of Geographic Atrophy Associated with Age-Related Macular DegenerationParticipants currently recruited/enrolled55-125 YearsNEI Central
17-C-0149Phase 2 Trial of Pembrolizumab in Relapsed and Refractory Gray-Zone Lymphoma (GZL), Primary Central Nervous System Lymphoma (PCNSL),and Other Extranodal Diffuse Large B-cell LymphomasNo longer recruiting/follow-up only18-125 YearsNCI Central
17-C-0137Leukapheresis for CAR or Adoptive Cell Therapy ManufacturingEnrolling by Invitation3-65 YearsNCI Central
17-C-0117A Phase 1/2a, Open-Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Anti-Tumor Activity of PEN-866 in Advanced Solid MalignanciesCompleted Study; data analyses ongoing18-125 YearsNCI Central
17-C-0102Phase II Trial of the Immune Checkpoint Inhibitor Nivolumab in Patients with Recurrent Select Rare CNS CancersParticipants currently recruited/enrolled18-99 YearsNCI Central
16-N-0072A Pilot Study of Adoptive Cellular Immunotherapy for Progressive Multifocal Leukoencephalopathy with Ex Vivo Generated Polyomavirus-Specific T-cellsCompleted Study; data analyses ongoing18-125 YearsNINDSCentral
16-N-0055The Pathological Basis of MRI Signal Changes in Multiple Sclerosis: A Longitudinal In Vivo-to-Postmortem StudyParticipants currently recruited/enrolled18-125 YearsNINDSCentral
16-C-0151Evaluation of the Natural History of and Specimen Banking for Patients with Tumors of the Central Nervous SystemParticipants currently recruited/enrolled18-125 YearsNCI Central
16-C-0034A Phase II Trial of Oral Pazopanib plus Oral Topotecan Metronomic Antiangiogenic Therapy for Recurrent Glioblastoma Multiforme (A) without Prior Bevacizumab Exposure and (B) after Failing Prior BevacizumabCompleted Study; data analyses ongoing18-125 YearsNCI Central
15-C-0067A Phase I/II Open Label, Dose Escalation Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell TransplantationParticipants currently recruited/enrolled18-125 YearsNCI Central
15-C-0029Phase I Dose Escalation Study of Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults with Recurrent or Refractory CD22-expressing B Cell MalignanciesParticipants currently recruited/enrolled3-39 YearsNCI Central
14-H-0155A Phase 1/2 Study Evaluating Gene Therapy by Transplantation of Autologous CD34+ Stem Cells Transduced Ex Vivo with the LentiGlobin BB305 Lentiviral Vector in Subjects with Severe Sickle Cell DiseaseNo longer recruiting/follow-up only18-50 YearsNHLBICentral
14-EI-0171The Focal Electro-Oculogram in Macular DiseaseCompleted Study; data analyses ongoing10-125 YearsNEI Central
14-CC-0143Sleep Disturbance and Relapse in Individuals with Alcohol Dependence: An Exploratory Mixed Methods StudyCompleted Study; data analyses ongoing18-125 YearsCC Central
14-C-0157Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib, Rituximab (TEDDI-R) in Primary CNS LymphomaParticipants currently recruited/enrolled18-125 YearsNCI Central
11-EI-0264A Pilot Study for the Evaluation of Minocycline as a Microglia Inhibitor in the Treatment of Central Retinal Vein OcclusionsCompleted Study; data analyses ongoing18-125 YearsNEI Central
11-EI-0147Longitudinal Investigation of Dark Adaptation in Participants with Age-Related Macular DegenerationParticipants currently recruited/enrolled50-125 YearsNEI Central
10-I-0148Natural History of Severe Allergic Inflammation and ReactionsParticipants currently recruited/enrolled2-80 YearsNIAIDCentral
10-I-0139Searching for Persistence of Infection in Lyme DiseaseCompleted Study; data analyses ongoing18-125 YearsNIAIDCentral
10-C-0086Comprehensive Omics Analysis of Pediatric Solid Tumors and Establishment of a Repository for Related Biological StudiesParticipants currently recruited/enrolled0-125 YearsNCI Central
09-I-0032Comprehensive Multimodal Analysis of Patients with Neuroimmunological Diseases of the CNSParticipants currently recruited/enrolled0-99 YearsNIAIDCentral
09-H-0225Nonmyeloablative Haploidentical Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Severe Congenital Anemias Including Sickle Cell Disease and Beta-ThalassemiaNo longer recruiting/follow-up only2-125 YearsNHLBICentral
08-H-0046Co-Infusion of Umbilical Cord Blood and Haploidentical CD34+ Cells Following Nonmyeloablative Conditioning as Treatment for Severe Aplastic Anemia and MDS Associated with Severe Neutropenia Refractory to Immunosuppressive TherapyCompleted Study; data analyses ongoing4-75 YearsNHLBICentral
08-C-0130A Phase II Trial of Peginterferon alfa-2b (PEG-Intron) for Neurofibromatosis Type 1 Related Unresectable, Symptomatic or Life-Threatening Plexiform NeurofibromasCompleted Study; data analyses ongoing0-21 YearsNCI Central
08-C-0079Natural History Study and Longitudinal Assessment of Children, Adolescents, and Adults with Neurofibromatosis Type 1No longer recruiting/follow-up only0-125 YearsNCI Central
07-N-0122Modulation of Motor Function by Stimulation of the Central and Peripheral Nervous SystemCompleted Study; data analyses ongoing18-125 YearsNINDSCentral
06-H-0190Treatment of T-Large Granular Lymphocyte (T-LGL) Lymphoproliferative Disorders with Alemtuzumab (Campath)Completed Study; data analyses ongoing18-85 YearsNHLBICentral
06-C-0219An Exploratory Study of Biologic and Pathophysiologic Effects of Radiation Therapy in Pediatric Patients with Central Nervous System TumorsCompleted Study; data analyses ongoing0-21 YearsNCI Central
05-H-0242A Pilot Study of Alemtuzumab (Campath) in Patients with Relapsed or Refractory Severe Aplastic AnemiaCompleted Study; data analyses ongoing2-110 YearsNHLBICentral
05-CC-0041Endothelial Cell Dysfunction in Pulmonary Arterial Hypertension: Biomarkers, Mechanisms of Disease and Novel Therapeutic TargetsCompleted Study; data analyses ongoing18-125 YearsCC Central
05-C-0252Phase III Randomized Study of R-CHOP v. Dose-Adjusted EPOCH-R with Molecular Profiling in Untreated de Novo Diffuse Large B-Cell LymphomasCompleted Study; data analyses ongoing18-125 YearsNCI Central
03-C-0278A Comparative Study of Pediatric CNS Tumor Activity as Assessed by 18F-FDG PET Imaging and Proton Magnetic Resonance Spectroscopic Imaging (1H-MRSI)Completed Study; data analyses ongoing1-21 YearsNCI Central
02-H-0250A Phase I/II Study of HLA-matched Mobilized Peripheral Blood Hematopoietic Stem Cell Transplantation for Advanced Mycosis Fungoides/Sezary Syndrome Using Nonmyeloablative Conditioning with Campath-1HCompleted Study; data analyses ongoing18-125 YearsNHLBICentral
00-H-0051Cutaneous Tumorigenesis in Patients with Tuberous SclerosisParticipants currently recruited/enrolled18-90 YearsNHLBICentral
97-CH-0076A Clinical and Genetic Investigation of Pituitary and HYPOTHALAMIC Tumors and Related DisordersParticipants currently recruited/enrolled3-70 YearsNICHDCentral
94-C-0074Treatment and Natural History Study of Lymphomatoid GranulomatosisParticipants currently recruited/enrolled12-125 YearsNCI Central
92-M-0174The Central Nervous System Effects of Pharmacologically Induced Hypogonadotropic Hypogonadism with and without Estrogen and Progesterone ReplacementCompleted Study; data analyses ongoing18-50 YearsNIMH Central
91-CC-0117Epidemiology, Infectivity and Natural History of Hepatitis C Virus Infection in a Blood Donor PopulationNo longer recruiting/follow-up only18-125 YearsCC Central
10 Center Drive,Bethesda, MD 20892 | Directions
Privacy Statement | Accessibility | Plain Language | FOIA | Disclaimer
Clinical Center | National Institutes of Health | HHS Vulnerability Disclosure | U.S. Department of Health and Human Services | USA.gov
NIH…Turning Discovery Into Health®